The AF–Heart Failure Continuum

Atrial fibrillation and heart failure are usually treated as separate diagnoses. The clinical evidence says otherwise. They share hemodynamic drivers, accelerate each other's progression, and frequently coexist in the same patient — often with one condition masking the onset of the other.

Data from STROKESTOP and STROKESTOP II quantify the risk: roughly one in five patients with screening-detected AF develops heart failure within six months, a greater-than-threefold increase compared to matched patients without AF. That risk is equivalent to clinically diagnosed AF — meaning the AF detected incidentally on a screening ECG carries the same downstream hazard as the AF a cardiologist already knows about.

Screening finds the signal. It doesn't manage the trajectory.

The problem isn't detection — AF screening tools are effective and increasingly available. The problem is what happens after a positive screen. Traditional care pathways are episodic, with follow-up visits spaced three to six months apart. They're fragmented, with cardiology and primary care operating in separate workflows. And they're reactive, waiting for symptoms or a hospitalization before escalating care. A patient screened positive for AF in January may not see anyone again until July — well past the six-month window where the steepest deterioration occurs.

From screening event to continuous execution

SYNC-PREVENT™ converts a screening event into a 365-day clinical execution pathway. It begins in the physician's office, where in-office diagnostic testing — digital ECG, cardiac auscultation for structural signals, noninvasive LVEDP measurement for early congestion — establishes an objective physiological baseline, not just a risk score.

Patients who screen positive move into continuous monitoring: daily biometrics tracking blood pressure, heart rate, weight, and rhythm. The system watches specifically for hemodynamic drift, volume overload trends, and blood pressure instability — the subclinical signatures of an AF-to-HF transition. AI-driven interpretation layers device data against biomarkers, medication adherence, and comorbidity context to reclassify risk dynamically rather than waiting for the next office visit to reassess.

“Screening identifies risk. What matters is what happens in the six months after that screen — whether the trajectory is watched continuously or checked episodically.”

The physician receives escalations when signals cross a threshold, not monthly summaries after the fact. Coordination spans cardiology, primary care, and electrophysiology through a single monitoring record. The goal is straightforward: detect the transition from AF to heart failure while it's still hemodynamic drift, not after it becomes a hospitalization.